Warning: Undefined variable $post_id in /var/www/vhosts/europe.thermoking.com/www.staging.europe.thermoking.com/httpdocs/wp-content/themes/thermoking/thetheme_template-parts/content.php on line 7
Warning: Undefined array key "available_in_tags" in /var/www/vhosts/europe.thermoking.com/www.staging.europe.thermoking.com/httpdocs/wp-content/themes/thermoking/thetheme_components/hero.php on line 48
Warning: Undefined array key "type" in /var/www/vhosts/europe.thermoking.com/www.staging.europe.thermoking.com/httpdocs/wp-content/themes/thermoking/thetheme_components/hero.php on line 75
/var/www/vhosts/europe.thermoking.com/www.staging.europe.thermoking.com/httpdocs/wp-content/themes/thermoking/thetheme_components/hero.php on line 80">
5th May 2021
Thermo King Ultra-low Temperature Storage Solutions Help va-Q-tec in COVID-19 Global Vaccine Distribution
Thermo King advances vaccine distribution across the globe with critical storage solutions and long-standing partnership with va-Q-tec.
Thermo KingĀ®, a global leader in intelligent end-to-end temperature-controlled cold chain solutions and a brand of Trane Technologies (NYSE: TT), is leveraging its well-established partnership with va-Q-tec by preconditioning their temperature storage elements and containers with its Cold Storage Solutions to meet the exact temperature requirementsĀ for reliable vaccine distribution.
va-Q-tec, a pioneer and manufacturer of highly efficient thermal containers and boxes for temperature-controlled logistics, equipped the majority of their current 40 worldwide stations with Thermo King Magnum PlusĀ® and SuperFreezer refrigerated containers. These Thermo King containers can maintain stable temperature set-points between -70 degrees Celsius to + 30 degrees Celsius allowing va-Q-tec to precondition the temperature storage elements (also referred to as PCM āphase changing materialsā) used in their passive containers and boxes to the precise temperature required by the pharmaceutical companies and ensure the best possible service quality.
āConsidering the urgent, global need for a COVID-19 vaccine, and the vast quantities of vaccine that need to be distributed, the world canāt afford breaks in the cold chain,ā said Francesco Incalza, president of Thermo King Europe, Middle East and Africa. āAt Thermo King we are helping ensure the vaccine gets to the people who need it, and that means working closely with industry leaders like va-Q-tec, with the pharma companies producing viable vaccines and the distribution companies they plan to work with. The most important thing is helping to support safe ā and fast ā delivery of the vaccine to people around the world.ā
āva-Q-tec has many years of experience with international pharmaceutical temperature controlled supply chains (TempChain) in many different temperature ranges, giving pharmaceutical companies access to worldās largest fleet of passively temperature-controlled high-tech rental containers,ā said Dr. Joachim Kuhn, CEO and founder of va-Q-tec. Ā āWe have been working with Thermo King for several years now, and their technology solutions have always offered optimal stability even in as low temperature as -70 degrees Celsius. We are very proud of the good, reliable collaboration.ā
Currently, Thermo King and va-Q-tec’s are providing solutions to transport vaccines in majority of the federal states in Germany, and also in Spain, Uruguay and Singapore among others.
For more information on Thermo Kingās expertise and solutions that can enable Pharmaceutical companies and their distributors to ensure the efficacy of their products through the entire cold chain, please visit www.europe.thermoking.com.
Warning: Undefined variable $relatedPostType in /var/www/vhosts/europe.thermoking.com/www.staging.europe.thermoking.com/httpdocs/wp-content/themes/thermoking/thetheme_template-parts/content.php on line 59
Related articles
The future is colder: pharma distribution in the age of mRNA vaccines
āItās plausible that Europe is moving toward a kind of pandemic end gameā. So said Hans Kluge, of the World Health Organizationās (WHO), amid suggestions the Omicron variant could infect 60% of Europeans by March 2022 ā and result in broad group immunity.
Finding the cure: meeting the challenge of global vaccine distribution
The pharma cold chain is a vital element in global healthcare, but itās an activity with little room for error ā and therefore in need of the very best in transport refrigeration.
Three cold chain business opportunities for personalized medicine
Personalized medicine is far more effective than traditional medicine. Is your fleet prepared to embrace this new trend?